Inflammasome Activation-Induced Hypercoagulopathy: Impact on Cardiovascular Dysfunction Triggered in COVID-19...

Area of Science:

• Immunology
• Virology
• Cardiology

Background:

• COVID-19, caused by SARS-CoV-2, is a severe global health crisis.
• Inflammasome activation is implicated in COVID-19 pathogenesis, linked to cytokine storm and hypercoagulopathy.
• The precise mechanisms of inflammasome involvement in COVID-19, especially concerning cardiovascular complications, require further elucidation.

Purpose of the Study:

• To explore the role of inflammasome activation in SARS-CoV-2 infection.
• To investigate the link between inflammasome activation, cytokine storm, hypercoagulopathy, and cardiovascular disorders in COVID-19.
• To highlight potential therapeutic strategies targeting inflammasomes for COVID-19 management.

Main Methods:

• Review of existing literature on inflammasome activation in viral infections and COVID-19.
• Analysis of studies linking SARS-CoV-2 to cardiovascular complications and hyperinflammation.
• Exploration of cellular targets and signaling pathways involved in inflammasome-mediated pathogenesis.

Main Results:

• Inflammasome activation, particularly NLRP3, is associated with cytokine storm and hypercoagulopathy in COVID-19 patients.
• SARS-CoV-2 infection triggers cardiovascular issues like myocardial injury and thromboembolism, partly via inflammasome pathways.
• Affected cells include pneumocytes, macrophages, endothelial cells, and dendritic cells.

Conclusions:

• Inflammasome activation is a key factor in COVID-19 severity, contributing to hyperinflammation and hypercoagulopathy.
• The interplay between inflammasomes and hypercoagulopathy in COVID-19 is critical for understanding disease progression.
• Targeting inflammasome activation presents a promising therapeutic avenue to mitigate severe COVID-19 and its cardiovascular sequelae.